Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.33 | N/A | +66400.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.33 | N/A | +66400.00% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS performance, highlighting their commitment to ongoing projects. However, they did not offer specific revenue guidance.
We are pleased with our EPS results this quarter.
While we did not provide revenue guidance, we are focused on our strategic initiatives.
IDEAYA Biosciences reported a significant EPS beat, but the stock fell by 2.81% following the announcement. The lack of revenue data and guidance may have contributed to investor caution. Overall, while the EPS figure is impressive, uncertainty around revenue could be weighing on investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Nov 3, 2025